
|Articles|April 1, 2003
- Psychiatric Times Vol 20 No 4
- Volume 20
- Issue 4
First Night On-Call, Coronary Care Unit
Poetry of the Times
Advertisement
I'm driving a knife-edge
mountain ridge at midnight,
no lines, no guard rails,
a semi screaming down my lane
ready to crush me with its cargo
of science I still need to learn.
A rusted out Chevy on my tail
scrapes an exhaust pipe and sends
sparks into darkness, their brief light
fading fast as facts I've memorized.
I don't know who will die tonight,
me or them, but I grip the wheel tight,
knuckles lit white by high-beams,
my own heart pounding, heading uphill,
engine moaning, pedal to the metal.
Articles in this issue
over 23 years ago
Global and Social Considerationsover 23 years ago
Security Alerts Trouble American Psycheover 23 years ago
Psychiatry's Hottest Niche Marketsover 23 years ago
The Last Frontier: Going Beyond the Limitsover 23 years ago
Secondary Traumatization in Mental Health Care Providersover 23 years ago
Changes in the Concept of PTSD and Traumaover 23 years ago
The DSM: Not Perfect, but Better Than the Alternativeover 23 years ago
Dump the DSM>!Advertisement
Related to this article

Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.

FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.

Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.

A remitted patient with ARFID faces panic after a crash, showing why recovery includes somatic fear, not just eating behavior.

Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.

Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.

Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder
3
Muscarinic Treatment for Schizophrenia: A Presynaptic Answer to a Presynaptic Problem
4
First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance
5

